BioMarin通过收购Inozyme Pharma加强酶疗法业务-动脉网

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

CISION 等信源发布 2025-05-16 19:30



可切换为仅中文







BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

BioMarin Pharmaceutical 标志 (PRNewsfoto/BioMarin Pharmaceutical Inc.)

Inozyme Pharma, Inc.

伊诺酶制药公司

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency

收购对BioMarin来说是强有力的战略契合，新增了INZ-701——一种正在开发用于治疗ENPP1缺乏症的三期酶替代疗法。

First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages

预计2026年初将首次获得儿童关键数据，有望于2027年上市；其他临床项目将扩展至各年龄段患者。

Potential First-in-Disease Treatment for ENPP1 Deficiency

针对ENPP1缺乏症的潜在首创治疗方案

Conference Call and Webcast Scheduled Today at

今天安排的电话会议和网络直播

8:45 a.m. ET

早上8点45分（东部时间）

SAN RAFAEL, Calif.

加利福尼亚州圣拉斐尔

and

和

BOSTON

波士顿

，

May 16, 2025

2025年5月16日

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:

/PRNewswire/ -- BioMarin制药公司（纳斯达克：

BMRN

贝米恩（BMRN）

) and Inozyme Pharma, Inc. (Nasdaq:

）和Inozyme制药公司（纳斯达克：

INZY

) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for

）今天宣布，BioMarin 已达成最终协议，将收购 Inozyme。

$4.00

4.00美元

per share in an all-cash transaction for a total consideration of approximately

每股的价格，全部以现金交易，总对价约为

$270 million

2.7亿美元

. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2025, subject to regulatory approval, successful completion of a tender offer and other customary closing conditions.

该交易已获得两家公司董事会的一致批准，预计将于2025年第三季度完成，但须经监管机构批准、成功完成要约收购及其他惯例交割条件。

The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones.

此次收购将加强BioMarin的酶疗法产品组合，新增一种处于后期阶段的酶替代疗法INZ-701，该疗法目前正被评估用于治疗外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）缺乏症，这是一种罕见、严重且进展性的遗传疾病，影响血管、软组织和骨骼。

The condition is associated with increased cardiovascular mortality risk across all age groups, especially in infants. It is also associated with severe rickets and osteomalacia in children and adults. Data from the first Phase 3 pivotal study of INZ-701 in children is expected in early 2026, with potential regulatory approval in 2027.

该病症与所有年龄段人群中心血管疾病死亡风险增加有关，尤其是在婴儿中。它还与儿童和成人中的严重佝偻病和骨软化症相关。INZ-701在儿童中的首个三期关键研究数据预计将在2026年初发布，并可能在2027年获得监管批准。

。

'BioMarin has been deeply committed to advancing enzyme therapies for children and adults living with serious genetic conditions for more than 25 years, and today's agreement builds on our legacy,' said

“BioMarin 在过去 25 年多的时间里，一直致力于为患有严重遗传病的儿童和成人推进酶疗法的发展，而今天的协议建立在我们的传承之上，”

Alexander Hardy

亚历山大·哈代

, President and Chief Executive Officer of BioMarin. 'This acquisition brings to BioMarin an important medicine that has the potential to be the first treatment for children and adults with ENPP1 Deficiency, improving care for people living with this serious condition. As BioMarin continues our transformation and delivers on our corporate strategy, we will continue to evaluate external innovation alongside internal innovation.

，BioMarin的总裁兼首席执行官。“此次收购为BioMarin带来了一种重要的药物，有可能成为针对ENPP1缺乏症儿童和成人患者的首个治疗方法，改善患有这一严重疾病人群的护理。随着BioMarin持续推进我们的转型并实现公司战略，我们将继续评估外部创新与内部创新相结合的机会。

We are in a strong financial position to bring in additional assets as we accelerate the development of medicines for patients with significant unmet need.' .

我们有足够的资金实力，在加快为存在巨大未满足需求的患者开发药物的同时购入更多资产。

'Today's announcement gives greater hope to patients who may benefit from INZ-701, a potentially transformative therapy that aims to address the underlying causes and systemic impacts of ENPP1 Deficiency,' said

“今天的公告为可能受益于INZ-701的患者带来了更大的希望，这是一种潜在的变革性疗法，旨在解决ENPP1缺乏症的根本原因及其系统性影响，”

Douglas A. Treco

道格拉斯·A·特雷科

, Ph.D., Chief Executive Officer and Chairman of Inozyme. 'BioMarin has paved the way over the past two and a half decades, successfully launching five first-in-disease enzyme therapies. I'd like to thank the team at Inozyme and our partners for their outstanding work and dedication, as we pass this important potentially life-changing therapy to the leading innovator in genetically defined conditions.'.

博士，Inozyme首席执行官兼董事长。“在过去的两个半十年里，BioMarin开创了道路，成功推出了五种针对疾病的首创酶疗法。我要感谢Inozyme团队和我们的合作伙伴的出色工作和奉献精神，因为我们正在将这种重要的、可能改变生命的疗法交给遗传定义疾病领域的领先创新者。”

INZ-701 and ENPP1 Deficiency

INZ-701与ENPP1缺乏症

INZ-701 is a potential first-in-class, subcutaneous enzyme replacement therapy that is being developed for infants, pediatric and adult patients with ENPP1 Deficiency across a continuum of phenotypes. In addition to the ongoing Phase 3 pivotal study in children, Inozyme is currently enrolling infants in a pivotal study, and a supportive study for adolescents and adults is being planned..

INZ-701 是一种潜在的首创新药，作为皮下酶替代疗法，正在为涵盖一系列表型的ENPP1缺乏症的婴儿、儿童和成人患者开发。除了正在进行的针对儿童的III期关键研究外，Inozyme公司目前还在一项关键研究中招募婴儿，并计划开展针对青少年和成人的支持性研究。

In a Phase 1/2 study of adults living with ENPP1 Deficiency, INZ-701 demonstrated a favorable safety profile, with no serious adverse events attributed to INZ-701. Improvements in pyrophosphate levels, bone mineralization biomarkers and quality of life were all observed, suggesting prospect for benefit in patients..

在一项针对ENPP1缺乏症成人患者的1/2期研究中，INZ-701表现出良好的安全性，未发生与INZ-701相关的严重不良事件。研究观察到焦磷酸盐水平、骨矿化生物标志物以及生活质量均有所改善，表明该药物有望为患者带来益处。

ENPP1 Deficiency is a lifelong, rare, progressive, multisystemic condition, caused by mutations in the

ENPP1缺乏症是一种终生的、罕见的、渐进的、多系统的疾病，由以下因素引起突变：

ENPP1

gene, leading to loss of ENPP1 enzymatic activity that results in low pyrophosphate, upregulation of fibroblast growth factor-23 and phosphate wasting. The condition affects blood vessels, soft tissues and bones. It is associated with high risk of cardiovascular mortality in patients of all ages, especially infants.

基因，导致ENPP1酶活性丧失，从而引起低焦磷酸盐、成纤维细胞生长因子-23上调和磷的浪费。这种情况会影响血管、软组织和骨骼。它与所有年龄段患者，尤其是婴儿，有很高的心血管疾病死亡风险相关。

It is also associated with severe rickets and osteomalacia in children and adults. Patients require considerable multidisciplinary lifelong medical and surgical management of complications. Currently there are no approved therapies for ENPP1 Deficiency..

它还与儿童和成人严重的佝偻病和骨软化症有关。患者需要多学科的终身医疗和手术来管理并发症。目前，尚无针对ENPP1缺乏症的获批疗法。

Terms of the Transaction

交易条款

Under the terms of the merger agreement, BioMarin will promptly commence a cash tender offer to acquire all of the outstanding shares of Inozyme common stock at a price of

根据合并协议的条款，BioMarin将迅速启动现金要约收购，以每股价格收购Inozyme所有已发行的普通股。

$4.00

4.00美元

per share. Inozyme's Board of Directors unanimously recommends that Inozyme's stockholders tender their shares in the tender offer.

每股。Inozyme董事会一致建议Inozyme的股东在要约收购中出让他们的股份。

The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Inozyme, the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and other customary conditions.

要约收购的完成取决于惯例的交割条件，包括至少过半数的Inozyme已发行股份的要约、1976年《哈特-斯科特-罗迪诺反垄断改进法》规定的等待期届满或终止，以及其他惯例条件。

Following the successful completion of the tender offer, a wholly owned subsidiary of BioMarin will merge with Inozyme and the outstanding Inozyme shares not tendered in the tender offer will be converted into the right to receive the same .

在要约收购成功完成后，BioMarin 的全资子公司将与 Inozyme 合并，而未在要约收购中出售的已发行 Inozyme 股份将被转换为接收相同对价的权利。

$4.00

4.00美元

per share in cash paid in the tender offer. The transaction is not subject to any financing condition.

每股以现金支付要约收购中的金额。本次交易不受任何融资条件的限制。

BioMarin also today reaffirmed previously provided full-year 2025 financial guidance, excluding the impact of the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing, as well as its plan to achieve 40% Non-GAAP Operating Margin in 2026..

BioMarin 今天还重申了此前提供的 2025 全年财务指导，不包括根据公认会计原则（GAAP）在交易完成时对该交易会计处理的影响，以及其在 2026 年实现 40% 非 GAAP 营业利润率的计划。

Advisors

顾问

Goldman Sachs & Co. LLC is acting as exclusive financial advisor to BioMarin, and Cooley LLP is serving as legal counsel. Centerview Partners LLC is acting as exclusive financial advisor to Inozyme, and Goodwin Procter LLP is serving as legal counsel.

高盛有限责任公司担任BioMarin的独家财务顾问，科利律师事务所担任法律顾问。Centerview Partners LLC担任Inozyme的独家财务顾问，Goodwin Procter LLP担任法律顾问。

Conference Call

电话会议

BioMarin will host a conference call and webcast to discuss the acquisition today,

BioMarin 将于今天举办电话会议和网络直播来讨论此次收购，

May 16, 2025

2025年5月16日

, at

，处于

8:45 a.m. ET

早上8点45分（东部时间）

. This event can be accessed through this

此事件可通过以下方式访问

link

链接

or on the investor section of the BioMarin website at

或在BioMarin网站的投资者部分

www.biomarin.com

。

U.S./Canada Dial-in Number: 888-596-4144

美国/加拿大拨打号码：888-596-4144

Replay Dial-in Number: 800-770-2030

重播拨入号码：800-770-2030

International Dial-in Number: 646-968-2525

国际拨入号码：646-968-2525

Replay International Dial-in Number: 609-800-9909

国际回拨电话号码：609-800-9909

Conference ID: 2239224

会议 ID：2239224

Conference ID: 2239224

会议ID：2239224

About

关于

BioMarin

BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The

BioMarin是一家全球生物技术公司，致力于将基因发现的希望转化为对每位患者生活产生深远影响的药物。

San Rafael, California

加利福尼亚州圣拉斐尔

-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world..

总部位于-的公司，成立于1997年，拥有八种商业疗法以及强大的临床和临床前管线，创新成果显著。BioMarin采用独特的药物发现与开发方法，致力于通过研发开创性类别的药物，充分释放基因科学的潜力，为全球患有基因定义疾病的患者提供新的可能。

To learn more, please visit

要了解更多信息，请访问

www.biomarin.com

。

About Inozyme

关于Inozyme

Inozyme Pharma is a clinical-stage biopharmaceutical company, with approximately 50 employees based in

Inozyme Pharma是一家临床阶段的生物制药公司，拥有约50名员工，总部位于

Boston

波士顿

. The company is dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate and adenosine levels.

公司致力于开发针对PPi-腺苷通路的创新疗法，这一通路是骨骼健康和血管功能的关键调节因子。该通路的紊乱是多种严重疾病的基础，包括ENPP1缺乏症。我们的主要研究性疗法INZ-701是一种ENPP1 Fc融合蛋白酶替代疗法，旨在恢复焦磷酸盐和腺苷水平。

INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions..

INZ-701目前正处于ENPP1缺乏症的晚期临床开发阶段，未来有望扩展到其他适应症，特别是那些由焦磷酸腺苷通路缺陷导致疾病病理的情况，包括ABCC6缺乏症和钙化防御。通过我们的开创性工作，我们旨在为受这些严重疾病影响的患者提供变革性的治疗选择。

To learn more, please visit

要了解更多信息，请访问

www.inozyme.com

。

Forward-Looking Non-GAAP Financial Information

前瞻性非GAAP财务信息

As described above, today BioMarin reaffirmed its plan to achieve 40% Non-GAAP Operating Margin in 2026. BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because BioMarin is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews; potential future asset impairments; gains and losses on investments; and other unusual gains and losses without unreasonable effort.

如上所述，BioMarin 今天重申了其在 2026 年实现 40% 非公认会计准则营业利润率的目标。BioMarin 不提供关于公认会计准则报告财务指标（收入除外）的指引，也不提供前瞻性非公认会计准则财务指标与最直接可比的公认会计准则报告财务指标的对账，因为 BioMarin 无法合理确定地预测由于其战略投资组合和业务运营模式审查、潜在未来资产减值、投资损益及其他异常损益所带来的财务影响，且进行此类预测需要不合理的努力。

These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors..

这些项目存在不确定性，取决于各种因素，并且可能对指导期内按公认会计原则报告的结果产生重大影响。因此，所提供的任何调节信息都可能暗示出一定程度的精确性，这可能会使投资者感到困惑或产生误导。

Non-GAAP Information

非GAAP信息

Non-GAAP Operating Margin percentage is defined by BioMarin as GAAP Income from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues.

非GAAP运营利润率百分比由BioMarin定义为：GAAP运营收入，不包括无形资产摊销、基于股票的补偿费用，并在某些期间排除某些其他特定项目，再除以GAAP总收入。

BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacturing, marketing and sale of innovative biologic therapies.

BioMarin 内部定期使用 GAAP 和非 GAAP 结果及预期来评估其财务运营表现，并评估与其主要业务活动相关的关键业务决策：发现、开发、制造、营销和销售创新生物疗法。

Because Non-GAAP Operating Margin percentage is an important internal measurement for BioMarin, BioMarin believes that providing this information in conjunction with BioMarin's GAAP information enhances investors' and analysts' ability to meaningfully compare BioMarin's results from period to period and to its forward-looking guidance, and to identify operating trends in BioMarin's principal business..

由于非GAAP运营利润率百分比是BioMarin的一项重要内部指标，BioMarin认为，将此信息与其GAAP信息结合提供，能够增强投资者和分析师有意义地比较BioMarin各期间结果及其前瞻性指导的能力，并识别BioMarin核心业务中的运营趋势。

Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with BioMarin's results of operations as determined in accordance with GAAP.

非GAAP财务指标不应单独考虑，或作为GAAP指标的替代品，或被视为优于可比的GAAP指标，并且应与根据GAAP编制的合并财务信息一并阅读。投资者应注意，非GAAP信息并非根据任何全面的会计规则或原则编制，且并未反映根据GAAP确定的BioMarin经营结果相关的所有金额。

Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that BioMarin may exclude for purposes of its Non-GAAP financial measures; likewise, BioMarin may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures.

投资者还应注意，这些非公认会计原则财务指标没有公认会计原则规定的标准化含义，因此对投资者的有用性存在局限性。此外，未来不时可能会有其他项目，BioMarin可能会为了其非公认会计原则财务指标的目的而排除；同样，BioMarin未来可能会停止排除其历史上为了其非公认会计原则财务指标的目的而排除的项目。

Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies..

由于定义的非标准化，BioMarin在本新闻稿中使用的非GAAP财务指标可能与其他公司使用的类似标题的指标计算方式不同，因此可能无法直接比较。

Forward-Looking Statements

前瞻性声明

This press release and the associated conference call contain forward-looking statements about, among other things, the proposed acquisition of Inozyme Pharma, Inc. (Inozyme) by BioMarin Pharmaceutical Inc. (BioMarin) and the business prospects of Inozyme and BioMarin, including, without limitation, statements about: the anticipated occurrence, manner and timing of the proposed tender offer and the closing of the proposed acquisition; the prospective benefits of the proposed acquisition, including expectations that it will strengthen BioMarin's enzyme therapies portfolio and be a strong strategic fit for BioMarin; Inozyme's product candidate INZ-701 and expectations regarding its ongoing development, including the potential for INZ-701 to be the first treatment for children and adults with ENPP1 Deficiency, the potential benefits of INZ-701 for patients, the anticipated timing for data from the first Phase 3 pivotal study of INZ-701 in children, the anticipated costs of developing INZ-701 and the potential regulatory approval of INZ-701 in 2027; potential revenue for INZ-701; additional INZ-701 clinical programs intended to expand to patients of all ages; the anticipated market for INZ-701; plans for an INZ-701 pivotal study for adolescents and adults; INZ-701's potential to expand into additional indications where deficiencies in the Pyrophosphate-Adenosine Pathway contribute to disease pathology; the accounting treatment of the potential acquisition under GAAP and its potential impact on BioMarin's financial results and financial guidance; BioMarin's plans for external innovation, including BioMarin being in a strong financial position to acquire additional assets; BioMarin's ability to execute additional transactions in future quarters; statements about BioMarin's fu.

本新闻稿和相关的电话会议包含关于BioMarin制药公司（BioMarin）拟收购Inozyme制药公司（Inozyme）及其他事项的前瞻性陈述，包括但不限于：拟议要约收购的发生、方式和时间安排以及拟议收购的完成；拟议收购的预期收益，包括其将加强BioMarin的酶疗法产品组合并成为BioMarin强有力的战略契合的预期；Inozyme的产品候选药物INZ-701及其开发进展的预期，包括INZ-701有望成为治疗ENPP1缺乏症儿童和成人的首个疗法、INZ-701对患者的潜在益处、INZ-701在儿童中的首次III期关键研究数据的预期时间、开发INZ-701的预期成本及INZ-701在2027年获得监管批准的潜力；INZ-701的潜在收入；计划扩展至所有年龄段患者的其他INZ-701临床项目；INZ-701的预期市场；青少年和成人中进行的INZ-701关键性研究计划；INZ-701在其他适应症中的扩展潜力，特别是那些由焦磷酸腺苷通路缺陷导致病理性疾病的适应症；根据GAAP对潜在收购的会计处理及其对BioMarin财务业绩和财务指导的潜在影响；BioMarin的外部创新计划，包括BioMarin具备强大财力以获取更多资产；BioMarin在未来季度执行额外交易的能力；关于BioMarin的未来计划。

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including, without limitation, with respect to: consummating the proposed acquisition in the anticipated timeframe, if at all; how many of Inozyme's stockholders will tender their stock in the tender offer; the possibility that competing offers or acquisition proposals will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the effects of the proposed acquisition (or the announcement thereof) on Inozyme's or BioMarin's stock price and/or BioMarin's or Inozyme's operating results; unknown or inestimable liabilities; the development, launch and commercialization of products and product candidates such as INZ-701, if approved; the successful completion of regulatory activities with respect to INZ-701; the parties' ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the proposed acquisition will not be realized or will not be realized within the expected time period and that BioMarin and Inozyme will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; obtaining and maintaining adequate coverage and re.

这些前瞻性陈述为预测性陈述，涉及风险和不确定性，可能导致实际结果与这些陈述存在重大差异。前瞻性陈述反映了当前的信念和期望；然而，这些陈述涉及固有的风险和不确定性，包括但不限于：是否能在预期的时间框架内完成拟议的收购；有多少Inozyme的股东会在要约收购中出售其股票；可能会出现竞争性报价或收购提议；交易的各项成交条件可能无法满足或被豁免，包括政府实体可能禁止、延迟或拒绝批准交易的完成（或仅在不利条件或限制下批准）；难以预测监管审批或行动的时间或结果（如有）；拟议收购（或其公告）对Inozyme或BioMarin股价和/或BioMarin或Inozyme经营业绩的影响；未知或无法估量的负债；如获批准，INZ-701等产品及候选产品的开发、上市和商业化；关于INZ-701的成功完成监管活动；双方实现拟议收购预期收益的能力，包括可能无法实现预期收益或无法在预期时间内实现收益，以及BioMarin与Inozyme可能无法成功整合或整合可能比预期更加困难、耗时或成本高昂；获得并维持足够的覆盖范围和再保险。

March 31, 2025

2025年3月31日

and Inozyme's Quarterly Report on Form 10-Q for the fiscal quarter ended

以及Inozyme截至本财政季度末的10-Q季度报告

March 31, 2025

2025年3月31日

, as such risk factors may be updated by any subsequent reports, as well as the Tender Offer Statement on Schedule TO and related tender offer documents to be filed by BioMarin and its acquisition subsidiary, Incline Merger Sub, Inc., and the Solicitation/Recommendation Statement on Schedule 14D-9 to be filed by Inozyme.

，因为此类风险因素可能会因任何后续报告而更新，BioMarin及其收购子公司Incline Merger Sub, Inc.将提交的附表TO要约收购声明及相关要约文件，以及Inozyme将提交的附表14D-9征集/建议声明也包含相关信息。

Stockholders of BioMarin and Inozyme are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin and Inozyme are under no obligation, and expressly disclaim any obligation, to update (publicly or otherwise) or alter any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise..

BioMarin 和 Inozyme 的股东被敦促不要过分依赖前瞻性陈述，这些陈述仅截至本文发布之日有效。BioMarin 和 Inozyme 没有任何义务，并明确声明不承担任何更新（无论是公开还是其他方式）或更改任何前瞻性陈述的义务，包括但不限于任何财务预测或指导，无论是否由于新信息、未来事件或其他原因。

BioMarin

is a registered trademark of BioMarin Pharmaceutical Inc. or its affiliates. Inozyme

是BioMarin制药公司或其附属公司的注册商标。Inozyme

is a registered trademark of Inozyme Pharma Inc. or its affiliates.

是Inozyme制药公司或其附属公司的注册商标。

Additional Information about the Acquisition and Where to Find It

关于收购的更多信息及其查找位置

The tender offer for all of the outstanding shares of Inozyme described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Inozyme, BioMarin or its acquisition subsidiary will file with the SEC upon commencement of the tender offer.

本通讯中描述的对Inozyme所有已发行股份的要约收购尚未开始。本通讯仅用于信息目的，既不是购买证券的要约，也不是出售任何证券的要约征集，也不能替代Inozyme、BioMarin或其收购子公司在要约收购开始时将向美国证券交易委员会提交的要约收购材料。

The solicitation and offer to tender and the offer to buy outstanding shares of Inozyme will only be made pursuant to a tender offer statement on Schedule TO, including an Offer to Purchase and related tender offer materials that BioMarin and its acquisition subsidiary, Incline Merger Sub, Inc., are expected to file with the SEC.

对Inozyme已发行股份的征求和收购要约以及购买要约，将仅根据BioMarin及其收购子公司Incline Merger Sub, Inc.预计向美国证券交易委员会（SEC）提交的TO表格上的要约声明进行，包括购买要约和相关的要约材料。

At the time the tender offer is commenced, BioMarin and its acquisition subsidiary will file a Tender Offer Statement on Schedule TO, and Inozyme will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), AS WELL AS THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO.

在要约收购开始时，BioMarin及其收购子公司将提交一份附表TO的要约收购声明，而Inozyme将针对该要约收购向美国证券交易委员会提交一份附表14D-9的征求/建议声明。要约收购材料（包括购买要约、相关转送函和某些其他要约文件）以及附表14D-9上的征求/建议声明将包含有关拟议收购及交易各方的重要信息。

INVESTORS AND STOCKHOLDERS OF INOZYME ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF INOZYME SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER.

强烈建议INOZYME的投资者和股东在这些文件可用时（以及每次可能不时修订或补充的文件）仔细阅读，因为它们将包含INOZYME的投资者和股东在就要约收购作出任何决定之前应考虑的重要信息。

The tender offer materials (including the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents.

要约收购材料（包括购买要约、相关的转送函和某些其他要约收购文件）。

www.sec.gov

. Copies of the documents filed with the SEC by BioMarin will be available free of charge on BioMarin's website at

BioMarin向美国证券交易委员会（SEC）提交的文件副本可免费在BioMarin的网站上获取，网址为

www.biomarin.com

. Copies of the documents filed with the SEC by Inozyme will be available free of charge on Inozyme's website,

Inozyme向美国证券交易委员会提交的文件副本将免费在Inozyme的网站上提供。

www.inozyme.com

, or by contacting Inozyme's investor relations department at

，或通过联系Inozyme的投资者关系部门

investorrelations@inozyme.com

投资者关系@伊诺酶.com

. The information contained in, or that can be accessed through, BioMarin's and Inozyme's websites is not a part of, or incorporated by reference herein. In addition to the Offer to Purchase, related Letter of Transmittal and certain other tender offer documents, and Solicitation/Recommendation Statement, BioMarin and Inozyme file annual, quarterly, and current reports, proxy statements and other information with the SEC.

BioMarin和Inozyme的网站中包含的或可通过其访问的信息，不是本文的一部分，也不并入本文。除购买要约、相关转送函、某些其他要约文件及征集/建议声明外，BioMarin和Inozyme还向美国证券交易委员会（SEC）提交年度、季度和当前报告、委托书声明及其他信息。

You may read any reports, statements or other information filed by BioMarin and Inozyme with the SEC for free on the SEC's website at .

您可以在SEC的网站上免费阅读BioMarin和Inozyme向SEC提交的任何报告、声明或其他信息。

www.sec.gov

。

BioMarin Contacts

BioMarin联系人

Traci McCarty, Investors

特雷西·麦卡蒂，投资者

BioMarin Pharmaceutical Inc.

BioMarin制药公司

(415) 455-7558